ID   SNU-5
AC   CVCL_0078
SY   SNU5; NCI-SNU-5
DR   BTO; BTO:0004986
DR   CLO; CLO_0009102
DR   EFO; EFO_0002351
DR   MCCL; MCC:0000436
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-5973
DR   BCRC; 60213
DR   BioSample; SAMN03470906
DR   BioSample; SAMN10987957
DR   cancercelllines; CVCL_0078
DR   Cell_Model_Passport; SIDM01144
DR   ChEMBL-Cells; CHEMBL3307458
DR   ChEMBL-Targets; CHEMBL614934
DR   Cosmic; 685587
DR   Cosmic; 687559
DR   Cosmic; 737363
DR   Cosmic; 848137
DR   Cosmic; 868237
DR   Cosmic; 908445
DR   Cosmic; 921596
DR   Cosmic; 1066231
DR   Cosmic; 1067203
DR   Cosmic; 1090451
DR   Cosmic; 1154648
DR   Cosmic; 1187293
DR   Cosmic; 1294960
DR   Cosmic; 1329187
DR   Cosmic; 1482072
DR   Cosmic; 1528872
DR   Cosmic; 1995597
DR   Cosmic; 2069773
DR   Cosmic; 2373750
DR   Cosmic; 2484972
DR   Cosmic; 2646589
DR   Cosmic-CLP; 908445
DR   DepMap; ACH-000303
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 908445
DR   GEO; GSM267422
DR   GEO; GSM267429
DR   GEO; GSM267436
DR   GEO; GSM267443
DR   GEO; GSM552374
DR   GEO; GSM562408
DR   GEO; GSM827398
DR   GEO; GSM828830
DR   GEO; GSM844703
DR   GEO; GSM887634
DR   GEO; GSM888720
DR   GEO; GSM1237681
DR   GEO; GSM1237706
DR   GEO; GSM1374893
DR   GEO; GSM1670275
DR   GEO; GSM1670473
DR   IARC_TP53; 307
DR   IARC_TP53; 21582
DR   IGRhCellID; SNU5
DR   KCLB; 00005
DR   LiGeA; CCLE_263
DR   LINCS_LDP; LCL-1890
DR   PharmacoDB; SNU5_1469_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0078
DR   PubChem_Cell_line; CVCL_0078
DR   Wikidata; Q54955215
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RX   PubMed=1676761;
RX   PubMed=2158397;
RX   PubMed=8806092;
RX   PubMed=8806095;
RX   PubMed=19956504;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=24807215;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29435981;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: MET genetic alteration cell panel (ATCC TCP-1036).
CC   Part of: Seoul National University (SNU) cell line collection.
CC   Population: Korean.
CC   Characteristics: MET-amplified, contains 8-9 copies of the gene (PubMed=29435981).
CC   Doubling time: 34 hours (PubMed=2158397; PubMed=29435981).
CC   HLA typing: A*24:02,26:01; B*35:01,40:05; C*03:03,03:03; DQA1*05:01,05:01; DQB1*03:09,03:09; DRB1*11:01,12:01 (PubMed=25960936).
CC   HLA typing: A*24:02,26:01; B*35:01,40:02; C*03:04,03:04 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly262_Ser269delGlyAsnLeuLeuGlyArgAsnSer (c.784_807del24); Zygosity=Unspecified (PubMed=1676761).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=65.54%; East Asian, South=33.69%; South Asian=0%; European, North=0%; European, South=0.76% (PubMed=30894373).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): ATCC; Cosmic-CLP; KCLB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8 (KCLB)
ST   D13S317: 8,9 (ATCC; Cosmic-CLP; PubMed=25877200)
ST   D16S539: 13
ST   D18S51: 13
ST   D19S433: 13.2,15
ST   D21S11: 29
ST   D2S1338: 17
ST   D3S1358: 16
ST   D5S818: 10
ST   D7S820: 8,12
ST   D8S1179: 14,15
ST   FGA: 21
ST   Penta D: 9,13
ST   Penta E: 18,19
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 15,16
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 42
//
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RA   Sekiguchi M., Suzuki T.;
RT   "Gastric tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.287-316; Academic Press; New York (1994).
//
RX   PubMed=1676761; DOI=10.1093/jnci/83.13.938;
RA   Kim J.-H., Takahashi T., Chiba I., Park J.-G., Birrer M.J., Roh J.K.,
RA   De Lee H., Kim J.-P., Minna J.D., Gazdar A.F.;
RT   "Occurrence of p53 gene abnormalities in gastric carcinoma tumors and
RT   cell lines.";
RL   J. Natl. Cancer Inst. 83:938-943(1991).
//
RX   PubMed=2158397;
RA   Park J.-G., Frucht H., La Rocca R.V., Bliss D.P. Jr., Kurita Y.,
RA   Chen T.-R., Henslee J.G., Trepel J.B., Jensen R.T., Johnson B.E.,
RA   Bang Y.-J., Kim J.-P., Gazdar A.F.;
RT   "Characteristics of cell lines established from human gastric
RT   carcinoma.";
RL   Cancer Res. 50:2773-2780(1990).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=8806095; DOI=10.1002/jcb.240630508;
RA   Park J.-G., Gazdar A.F.;
RT   "Biology of colorectal and gastric cancer cell lines.";
RL   J. Cell. Biochem. 63 Suppl. 24:131-141(1996).
//
RX   PubMed=19956504; DOI=10.4143/crt.2005.37.1.1;
RA   Ku J.-L., Park J.-G.;
RT   "Biology of SNU cell lines.";
RL   Cancer Res. Treat. 37:1-19(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24807215; DOI=10.1038/ncomms4830;
RA   Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M.,
RA   Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M.,
RA   Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C.,
RA   Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G.,
RA   Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S.,
RA   Firestein R., Zhang Z.-M.;
RT   "Integrated exome and transcriptome sequencing reveals ZAK isoform
RT   usage in gastric cancer.";
RL   Nat. Commun. 5:3830.1-3830.8(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29435981; DOI=10.1002/ijc.31304;
RA   Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C.,
RA   Kragh M., Horak I.D., Chung H.C., Rha S.Y.;
RT   "Forty-nine gastric cancer cell lines with integrative genomic
RT   profiling for development of c-MET inhibitor.";
RL   Int. J. Cancer 143:151-159(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//